As of May 27
| +1.86 / +4.26%|
The 9 analysts offering 12-month price forecasts for Pacira Pharmaceuticals Inc have a median target of 75.00, with a high estimate of 113.00 and a low estimate of 59.00. The median estimate represents a +64.62% increase from the last price of 45.56.
The current consensus among 9 polled investment analysts is to Buy stock in Pacira Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.